Vaxxinity Inc (VAXX)
0.09
+0.04
(+80.00%)
USD |
OTCM |
Sep 19, 10:11
Vaxxinity Net Income (Quarterly): -11.39M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -11.39M |
September 30, 2023 | -13.14M |
June 30, 2023 | -13.98M |
March 31, 2023 | -18.42M |
December 31, 2022 | -20.46M |
September 30, 2022 | -19.25M |
June 30, 2022 | -17.25M |
March 31, 2022 | -18.26M |
Date | Value |
---|---|
December 31, 2021 | -47.86M |
September 30, 2021 | -30.39M |
June 30, 2021 | -26.91M |
March 31, 2021 | -32.02M |
December 31, 2020 | -12.72M |
September 30, 2020 | -16.46M |
June 30, 2020 | -7.061M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-47.86M
Minimum
Dec 2021
-7.061M
Maximum
Jun 2020
-20.37M
Average
-18.26M
Median
Mar 2022
Net Income (Quarterly) Benchmarks
CEL-SCI Corp | -6.857M |
AIM ImmunoTech Inc | -1.836M |
IGC Pharma Inc | -2.378M |
NovaBay Pharmaceuticals Inc | -1.585M |
Protalix BioTherapeutics Inc | -2.203M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 11.65M |
EPS Diluted (Quarterly) | -0.09 |
Enterprise Value | -8.890M |
Earnings Yield | -500.0% |
Normalized Earnings Yield | -1117.83 |